Acasti pharma receives fda response to trilogy 1 briefing package

Acasti pharma receives fda response to trilogy 1 briefing package.acasti pharma inc - fda has provided acasti with a written response to its type c meeting request and briefing package.acasti pharma - fda confirmed that it will require pivotal efficacy analyses for trilogy 2 to be performed on full intent to treat population.
ACST Ratings Summary
ACST Quant Ranking